来自:中国糖尿病杂志 编辑:袁宁|点击数:|2016-03-04
【提要】 非酒精性脂肪性肝病(NAFLD)是与IR、肥胖和高脂血症密切相关的临床综合征。IR是T2DM和NAFLD共同的发病机制之一。一些降糖药物除降糖作用外还有控制体重、调节血脂和改善IR等特点,但有的本身具有药物性肝损害(DILI)。降糖药物是否对NAFLD产生影响尚无定论,本文就各类降糖药物和NAFLD的相关研究进展作一综述。
【关键词】 非酒精性脂肪性肝病;糖尿病,2型;胰岛素抵抗
Research progress of hypoglycemic agents and non-alcoholic fatty liver disease
【Summary】 Non-alcoholic fatty liver disease (NAFLD) is a clinical syndrome closely associated with IR, obesity and hyperlipidemia. IR plays a role in both NAFLD and T2DM pathogenesis. Some hypoglycemic agents can control body weight; regulate blood lipid and lower insulin resistance beside their anti-hyperglycemic effects. However, some of them can cause drug-induced liver injury (DILI). Whether hypoglycemic agents have any effect on NAFLD was unknown. Here we summarize the research progress in a variety of hypoglycemic agents and NAFLD for reference.
【Key words】 Non-alcoholic fatty liver disease (NAFLD);Diabetes mellitus, type 2;Insulin resistance (IR)
版权所有:《中国糖尿病杂志》社 主管单位:中华人民共和国教育部 主办单位:北京大学
地址:北京市西城区大红罗厂街1号 邮编:100034 电话(传真):010-88505683
中国糖尿病杂志社版权所 京ICP备11029051号-1 Powered by JiuduCMS 技术支持:九度创想